GlassScriptPhysician profile
Sandra S Daccarett
NPI 1093089245
$5,169.81
in general payments reported to CMS, 2019-2025
34 companies · $2,211 in 2025
The $2,211 reported for 2025 was more than what 96% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $414 · 2022: $966 · 2023: $336 · 2024: $1,242 · 2025: $2,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,789.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $658.51 | 2024-2025 | Briviact, Nayzilam |
| Janssen Pharmaceuticals, INC | $635.56 | 2021-2023 | Xarelto |
| Eisai INC. | $578.83 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $433.40 | 2021-2023 | Farxiga |
| Alexion Pharmaceuticals, INC. | $353.15 | 2024-2025 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.96 | 2022-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $246.41 | 2025 | Acthar |
| Abbvie INC. | $229.92 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $227.53 | 2022 | |
| Lilly USA, LLC | $194.17 | 2022-2025 | Zepbound, Jardiance, Emgality |
| Lundbeck LLC | $156.72 | 2024-2025 | Vyepti |
| Merz Pharmaceuticals, LLC | $153.41 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Neurelis, INC. | $110.09 | 2024-2025 | Valtoco |
| Pfizer INC. | $105.78 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $68.76 | 2024 | Ingrezza |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $63.00 | 2025 | Symbravo |
| Ani Pharmaceuticals, INC. | $60.92 | 2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $57.34 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $50.77 | 2025 | Austedo Xr |
| Amgen INC. | $49.05 | 2023 | Repatha |
| Sk Life Science, INC. | $45.68 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $41.29 | 2025 | Rexulti |
| Exact Sciences Corporation | $40.33 | 2024 | Cologuard Collection Kit |
| Emd Serono, INC. | $38.77 | 2024 | |
| Genentech USA, INC. | $38.63 | 2025 | Ocrevus Zunovo |
| Ge Healthcare | $31.16 | 2025 | |
| Tanabe Pharma America, INC. | $30.00 | 2025 | Radicava |
| Scilex Pharmaceuticals INC. | $24.32 | 2024 | |
| Jazz Pharmaceuticals INC. | $22.52 | 2025 | |
| Acadia Pharmaceuticals INC | $22.35 | 2025 | Daybue |
| Collegium Pharmaceutical, INC. | $22.01 | 2025 | Jornay Pm |
| Servier Pharmaceuticals LLC | $21.83 | 2024 | |
| Kyowa Kirin, INC. | $18.40 | 2024 | Nourianz |
| Biogen, INC. | $18.24 | 2025 | Leqembi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Daccarett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.